Lenalidomide (Revlimid™), adriamycin and dexamethasone chemotherapy (RAD) is safe and effective in treatment of relapsed multiple myeloma -: First results of a german multicenter phase I/II trial.

被引：0
|
作者：
Knop, Stefan
Gerecke, Christian
Topp, Max S.
Liebisch, Peter
Hess, Georg
Kotkiewitz, Sandra
Einsele, Hermann
Bargou, Ralf
机构：
[1] Univ Hosp, Wurzburg, Germany
[2] Charite Univ Med Berlin, Berlin, Germany
[3] Univ Hosp, Ulm, Germany
[4] Univ Hosp, Mainz, Germany
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
408
引用
收藏
页码：125A / 125A
页数：1
相关论文
共 50 条
  • [41] Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma
    Reece, Donna E.
    Masih-Khan, Esther
    Atenafu, Eshetu G.
    Jimenez-Zepeda, Victor H.
    Anglin, Peter
    Chen, Christine
    Kukreti, Vishal
    Mikhael, Joseph R.
    Trudel, Suzanne
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (01) : 46 - 54
  • [42] Mature results of MM-011: A phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma
    Lazaryan, Aleksandr
    Hussein, Mohamad A.
    Reu, Frederic J.
    Faiman, Beth
    Habecker, Becky
    Karam, Mary Ann
    Reed, Janice
    Hamilton, Kimberly
    Waksman, Joel
    Bruening, Kellie
    Srkalovic, Gordan
    Andresen, Steven
    Kalaycio, Matthew
    Sweetenham, John W.
    Sobecks, Ronald
    Dean, Robert
    Knight, Robert
    Zeldis, Jerome B.
    Baz, Rachid
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (04) : 349 - 354
  • [43] Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
    Marc-Andrea Baertsch
    Jana Schlenzka
    Elias K. Mai
    Maximilian Merz
    Jens Hillengaß
    Marc S. Raab
    Dirk Hose
    Patrick Wuchter
    Anthony D. Ho
    Anna Jauch
    Thomas Hielscher
    Christina Kunz
    Steffen Luntz
    Stefan Klein
    Ingo G. H. Schmidt-Wolf
    Martin Goerner
    Martin Schmidt-Hieber
    Peter Reimer
    Ullrich Graeven
    Roland Fenk
    Hans Salwender
    Christof Scheid
    Axel Nogai
    Mathias Haenel
    Hans W. Lindemann
    Hans Martin
    Richard Noppeney
    Katja Weisel
    Hartmut Goldschmidt
    BMC Cancer, 16
  • [44] Combined Bendamustine, Prednisolone and Lenalidomide (RBP) In Refractory or Relapsed Multiple Myeloma. First Results of a Phase I Clinical Trial
    Ponisch, Wolfram
    Heyn, Simone
    Wagner, Ina
    Mohren, Martin
    Hoffmann, Franz-Albert
    Schueler, Frank
    Schmalfeld, Marion
    Al-Ali, Haifa K.
    Jaekel, Nadja
    Niederwieser, Dietger W.
    BLOOD, 2010, 116 (21) : 823 - 824
  • [45] Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
    Baertsch, Marc-Andrea
    Schlenzka, Jana
    Mai, Elias K.
    Merz, Maximilian
    Hillengass, Jens
    Raab, Marc S.
    Hose, Dirk
    Wuchter, Patrick
    Ho, Anthony D.
    Jauch, Anna
    Hielscher, Thomas
    Kunz, Christina
    Luntz, Steffen
    Klein, Stefan
    Schmidt-Wolf, Ingo G. H.
    Goerner, Martin
    Schmidt-Hieber, Martin
    Reimer, Peter
    Graeven, Ullrich
    Fenk, Roland
    Salwender, Hans
    Scheid, Christof
    Nogai, Axel
    Haenel, Mathias
    Lindemann, Hans W.
    Martin, Hans
    Noppeney, Richard
    Weisel, Katja
    Goldschmidt, Hartmut
    BMC CANCER, 2016, 16
  • [46] Combination of bortezomib, melphalan, prednisone and thalidomide (VMPT) for relapsed multiple myeloma: Results of a phase I/II clinical trial.
    Palumbo, Antonio
    Ambrosini, Maria Teresa
    Benevolo, Giulia
    Pregno, Patrizia
    Pescosta, Norbert
    Callea, Vincenzo
    Cangialosi, Clotilde
    Caravita, Tommaso
    Morabito, Fortunato
    Musto, Legrino
    Bringhen, Sara
    Gay, Francesca
    Rus, Cecilia
    Boccadoro, Mario
    BLOOD, 2006, 108 (11) : 125A - 125A
  • [47] Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma
    Broijl, Annemiek
    Kersten, Marie-Jose
    Alemayehu, Wendimagegn Ghidey
    Levin, Mark-David
    de Weerdt, Okke
    Vellenga, Edo
    Meijer, Ellen
    Wittebol, Shulamit
    Tanis, Bea C.
    Cornelisse, Petra B.
    Stevens-Kroef, Marian
    Bos, Gerard M. J.
    Wijermans, Pierre W.
    Lokhorst, Henk
    Sonneveld, Pieter
    HAEMATOLOGICA, 2016, 101 (04)
  • [48] Phase I/II Trial of Lenalidomide, Bortezomib, Doxil, and Dexamethasone in Front-Line Multiple Myeloma
    Jakubowiak, A. J.
    Hofmeister, C.
    Campagnaro, E.
    Kendall, T.
    Zimmerman, T.
    Schlossman, R.
    Reece, D.
    Lonial, S.
    Hari, M.
    Hector-Word, Z.
    Griffith, K.
    Tendler, C.
    Esseltine, D. L.
    Bock, T.
    Kaminski, M.
    Dollard, A.
    Kelley, S.
    Anderson, K. C.
    Richardson, P. G.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S45 - S46
  • [49] Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma
    Haruhito Totani
    Masaki Ri
    Chie Kato
    Takahiro Nakashima
    Nana Suzuki
    Shinya Hagiwara
    Takashi Kanamori
    Satsuki Murakami
    Arisa Masuda
    Shiori Kinoshita
    Takashi Yoshida
    Tomoko Narita
    Asahi Ito
    Shigeru Kusumoto
    Takashi Ishida
    Hirokazu Komatsu
    Shinsuke Iida
    International Journal of Hematology, 2016, 103 : 316 - 321
  • [50] Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma
    Totani, Haruhito
    Ri, Masaki
    Kato, Chie
    Nakashima, Takahiro
    Suzuki, Nana
    Hagiwara, Shinya
    Kanamori, Takashi
    Murakami, Satsuki
    Masuda, Arisa
    Kinoshita, Shiori
    Yoshida, Takashi
    Narita, Tomoko
    Ito, Asahi
    Kusumoto, Shigeru
    Ishida, Takashi
    Komatsu, Hirokazu
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (03) : 316 - 321
12345